Pharmacogenetic studies have identified the non-synonymous single nucleotide polymorphism (A118G) in the human mu opioid receptor (MOR) gene (OPRM1) as a critical genetic variant capable of altering the efficacy of opioid therapeutics. To date few studies have explored the potential impact of the OPRM1 A118G polymorphism on the pharmacological effects of buprenorphine (BPN), a potent MOR partial agonist and kappa opioid receptor antagonist, which is approved by the FDA for the treatment of opioid addiction and chronic pain. The goal of these studies was to determine whether the MOR-mediated behavioral effects of BPN were altered in the Oprm1 A112G mouse model of the human OPRM1 A118G SNP. All studies were conducted in female, AA, AG and GG mice. BPN's maximal analgesic effect in the hot plate test was significantly blunted in AG and GG mice compared to wild type AA mice. Similarly, the BPN-induced reduction of latency to consume food in the novelty induced hypophagia test was blocked entirely in AG and GG mice compared to their AA littermates. In addition, GG mice exhibited marked reductions in psychostimulant hyperlocomotor activity compared to the AA group. In contrast, reduced immobility in the forced swim test, an effect of BPN mediated by kappa opioid receptors, was not affected by genotype. These studies demonstrate the ability of the Oprm1 A112G SNP to attenuate the analgesic, anxiolytic and hyperlocomotor effects of BPN. Overall, these data suggest that the OPRM1 A118G SNP will significantly impact the clinical efficacy of BPN in its therapeutic applications.
Introduction
Pharmacogenetic studies have highlighted the ability of specific genetic variants to alter the effectiveness of opioid therapeutics (Crist and Berrettini, 2014; Reed et al., 2014) . One of these variants, a non-synonymous single nucleotide polymorphism (rs1799971 or A118G) in the human mu opioid receptor (MOR) gene (OPRM1) (Bergen et al., 1997; Bond et al., 1998) , is distributed widely among various populations. The A118G SNP corresponds to an amino acid substitution of asparagine (N) to aspartic acid (D) at position 40 in the N-glycosylation site of the receptor, resulting in protein instability and reduced expression of MORs at the cell surface, changes that have been recapitulated using in vitro and murine models Mague et al., 2009; Oertel et al., 2012; Zhang et al., 2005) . This SNP is most frequently observed in individuals of Asian (49e60%) and European ancestry (15e30%) (Gelernter et al., 1999; Mura et al., 2013) . Subjective pain scores are noticeably higher in carriers of the G allele and they require significantly larger doses of opioid analgesics to alleviate their pain (Baber et al., 2016; Bonenberger et al., 2015; Chou et al., 2006b; Lopez Soto and Catanesi, 2015; Sia et al., 2008) . In addition, the G allele is associated with enhanced rewarding effects of alcohol and nicotine and marked deficits in fronto-striatal inhibitory control (Bach et al., 2015; Courtney et al., 2013; Ray et al., 2006) , indicating that this SNP may be associated with vulnerability to substance abuse.
To investigate the functional consequences of this SNP various in vitro and murine models have been generated. A knock-in mouse was developed that possesses the mouse-equivalent SNP of the human A118G SNP in the murine Oprm1 gene (Mague et al., 2009 ).
This mouse model recapitulates many of the traits induced by this SNP in humans, including lower levels of Oprm1 expression, reduced binding affinity and efficacy of MOR agonists, and altered behavioral response to drugs of abuse (Zhang et al., 2015; Wang et al., 2014; Huang et al., 2012; Wang et al., 2012; Mague et al., 2009) . In a complimentary approach, a different mouse line was generated that expresses humanized receptors with and without the A118G variant (Ramchandani et al., 2011) . The effects of morphine but not fentanyl on intracranial self-stimulation and dopamine release in the nucleus accumbens were blunted in the humanized mouse model of the OPRM1 A118G polymorphism . Using the same model, trigeminal ganglion neurons isolated from mice with the G allele exhibited blunted inhibition of Ca 2þ channels following morphine but not fentanyl administration ex vivo (Mahmoud et al., 2011) . These ligandspecific effects of the OPRM1 A118G are also evident in humans, where hydromorphone failed to adequately alleviate pain in carriers of the G allele following caesarian section (Boswell et al., 2013) whereas the G allele was associated with better epidural analgesia with fentanyl during labor compared to AA women (Song et al., 2013) . Buprenorphine (BPN) is a potent partial agonist at MORs and a kappa opioid receptor (KOR) antagonist (Cowan et al., 1977) that is commonly used for the treatment of opioid addiction and chronic pain. However, few studies have evaluated the consequences of the A118G SNP in relation to responses to BPN. A small clinical study identified a genotype dependent effect of BPN on HPA axis reactivity in heroin addicts, where BPN-maintained subjects with the AG/GG genotype exhibited greater attenuation of metyrapone provoked ACTH release compared to AA carriers (Kakko et al., 2008) . In addition to the treatment of opioid addiction and chronic pain, compelling clinical (Karp et al., 2014; Ehrich et al., 2015) and preclinical evidence (Falcon et al., 2016) have recently highlighted the potential antidepressant effects of BPN. As such, BPN is likely to be repurposed for the treatment of major depressive disorder (MDD) in the near future it would be informative to evaluate the influence of the A118G SNP on a range of behavioral phenotypes produced by BPN, that are known to be mediated by different mechanisms.
Gender specific determinants of neuropsychiatric disorders have not been adequately reflected in preclinical or clinical evaluation of novel antidepressant therapeutics. Per world health organization figures, MDD comprises 49% of all neuropsychiatric disorders reported in females and only 28% in males (Marcus et al., 2005; Weller et al., 2006) . To date, all preclinical work evaluating BPN in the context of MDD has been reported in males. Therefore, the goal of these studies was twofold, to determine whether female mice were sensitive to the antidepressant and anxiolytic action of BPN and to assess the impact of the A118G SNP using a murine model of this SNP, Oprm1 A112G, on BPN's effects in murine behavioral tests known to be mediated by MORs and KORs.
Materials and methods

Animals
Female C57BL/6J mice, 8 weeks of age when obtained from The Jackson Laboratory (Bar Harbor, MA), were used to evaluate the dose-response curve for BPN in the novelty-induced hypophagia test. For all other tests female Oprm1-A112G mice, with the following genotypes, A/A, A/G and G/G were used. These mice were generated on a C57BL/6 genetic background, and bred using a heterozygous breeding scheme as described previously (Mague et al., 2009) . Briefly site-directed mutagenesis introduced the polymorphism into exon 1 of the Oprm1 gene, where an adenine (A) nucleotide at position 112 was changed to a guanine (G) This substitution is equivalent to that in the human OPRM1 gene at position 118. All mice (8e19 weeks, 18e26 g) were housed in cages of two and maintained on a 12-h/12-h light/dark cycle with food and water available ad libitum. All studies were approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania and conducted in accordance to PHS policy.
Drugs
Buprenorphine hydrochloride (BPN) was provided by the Research Technology branch of the National Institute on Drug Addiction (NIDA, Bethesda, MD, USA). For all studies BPN was dissolved in vehicle (sterile HPLC grade water, MilliQ system, Millipore, Billerica MA, US), and sonicated for 15 min. Control mice were administered vehicle. Chlordiazepoxide (CDP, SigmaAldrich, St Louis MO, USA) was dissolved in sterile 0.9% saline (Hospira Inc., King of Prussia, PA, USA). Control mice received sterile saline. All compounds were prepared freshly on each experimental day and were administered using a 10 ml/kg injection volume.
Analgesia
The nociceptive threshold for analgesia was examined with a hot-plate analgesia meter (Columbus Instruments), set at a constant surface temperature of 55 C. This temperature was sufficient to cause thermal nociception without harming the sensitive tissue on the paws. A small plastic cage surrounding the hot-plate prevented the animal from leaving the plate surface. Cumulative dosing was conducted as follows. Baseline values were recorded from mice on the first exposure to the hot plate, where the latency to lick the hind-paw or jump was recorded. As soon as the mice displayed either of these behaviors, or reached the predetermined cut-off time of 60 s, mice were immediately removed from the hotplate. Mice were then administered the first dose of BPN, returned to their home cage and retested on the hot plate 30 min later. This process was repeated for all mice, which received doses of 0, 0.1, 0.2, 0.7, and 2 mg/kg, tested at 30 min intervals. The cumulative dose of the final injection of BPN was 3 mg/kg. Data is calculated as follows, ((observed response -baseline response)/(60 -baseline response)*100) and presented as percentage Maximum Possible Effect (%MPE).
Novelty induced hypophagia (NIH)
We have previously determined that the MOR-agonist induced hyperactivity of buprenorphine is not observed 24 h post administration (Falcon et al., 2015) and have conducted the NIH test at this time point to ensure that hyperactivity does not confound the outcome of the test. Animals were trained to consume a palatable food (peanut butter chips, Nestle) in the home cage for 12 days to establish stable latencies to consume the chips (Balu et al., 2009 ). Mice were housed in cages of two and had free access to chow up until training or testing session. On each training day, mice were separated with an opaque Plexiglas divider in the home cage 60 min prior to presentation of the food in a designated testing room. Each mouse was individually presented with chips (1.4 g) for 15 min, following which the divider was removed and mice returned to the colony room. Inclusion in the study required mice to exhibit latencies of 30 s over three consecutive days. BPN was shown to be effective in the NIH test 24 h post administration (Falcon et al., 2015) ; mice were injected with saline immediately following the last training exposure, 24 h prior to testing. As CDP is effective acutely, a separate cohort of mice was injected 30 min prior to testing. On the test day, testing was conducted in a different room to training. Each mouse was placed in a novel environment, consisting of a polycarbonate cage (48 L Â 26 W Â 20H cm) with no bedding, brightly lit (800 Lux) in a room illuminated by low light (400 Lux). A novel smell was introduced to the cage by cleaning it with diluted dish soap (Lemon Joy). Latency to begin eating the familiar palatable food in the center of the novel environment was then measured. The duration of the test was 15 min. If the mouse failed to approach and consume the food within this time, a latency value of 900 s was assigned to the mouse for data analysis.
Locomotor activity (LMA)
MOR agonists including BPN produce robust hyperlocomotor activity immediately following administration (Crawly et al., 1997; Falcon et al., 2015) . Therefore, activity was measured 30 min after BPN treatment in a cage identical to the dimensions of the home cage (28.9 Â 17.8 Â 12 cm) for 1 h. The cage was placed inside an infrared sensitive motion detection system (30 Â 24 Â 8 cm) with an 8-beam photocell array strip (Med Associates Inc, St. Albans, VT). The number of crosses and rearing activity were measured for all mice.
Forced swim test (FST)
The FST was conducted 24 h post BPN administration, at a time point where the initial hyperactivity induced by BPN is no longer evident (Falcon et al., 2015) . Swim sessions were conducted 24 h after treatment with BPN (0.25 mg/kg). Briefly, mice were placed in individual polycarbonate cylinders (25.3 cm tall Â 22.2 cm) filled to a depth of 15 cm with water (25 ± 1 C) that was changed between each animal. Test sessions were 6 min in duration, recorded from an overhead view and scored by a blinded observer. Immobility, defined as making only the movements necessary to maintain the head above the water, was scored in the last four minutes of the 6 min test (Lucki et al., 2001 ).
Statistical analysis
All data are expressed as mean ± SEM and analyzed using Graph Pad Prism 7.0 (La Jolla, CA). Two-way repeated measures ANOVA were used to test for significant interactions of genotype x cumulative BPN dose on antinociception in the hot plate test and genotype x training day on dependent variables in the NIH training phase. A one-way ANOVA with Dunnett's multiple comparisons tests was used to determine statistical significance in the BPN doseresponse experiment in the NIH test conducted using WT female mice. For all other dependent variables, two-way ANOVA were used to test for genotype Â treatment interactions. Where appropriate, Tukey's multiple comparison tests were used for post hoc analysis. A p value of <0.05 was deemed to be statistically significant.
Results
BPN-induced analgesia is blunted by the Oprm1 A112G polymorphism
Baseline levels of response did not differ between groups, AA: 11.4 ± 1.2 s, AG 14.1 ± 1.2 s and GG 11.2 ± 1.1 s. However, a significant genotype Â treatment interaction was observed on %MPE of BPN measured in the hot plate test (F 8, 195 ¼ 3.072, p ¼ 0.0028), as shown in Fig. 1 . Multiple comparisons revealed that the analgesic response to BPN was dramatically blunted in GG mice, which differed significantly from AA mice at cumulative doses of 1 mg/kg (p < 0.01) and 3 mg/kg (p < 0.001). Similarly the analgesic effect of BPN was diminished in AG mice compared to AA mice at cumulative doses of 1 and 3 mg/kg (p < 0.01).
Genotype differences observed during the early training phase of the NIH test
As mice are neophobic, the NIH test requires prior exposure to a period of training. Typically mice will approach and consume a palatable food in less than 30 s after several days of training. Mice were included in the study when they demonstrated three consecutive days of latencies <30 s. During the initial stages of training, a significant genotype x training day interaction was observed in latency to consume the peanut butter chips (F 22, 957 ¼ 1.691, p ¼ 0.024, data not shown). AA mice trained significantly faster than AG and GG mice. Tukey's multiple comparison test showed a significant difference in the latencies of AA and GG mice on day 3 (p < 0.01), day 4 (p < 0.05) and day 6 (p < 0.05). During the following 6 days of training no genotype differences were observed. All but 2 mice reached criterion by day 12 (one AG and one AA were excluded from the study) and similar approach latency baselines were evident for all groups prior to testing (AA 10.50 ± 1.86 s; AG 14.70 ± 1.62 s; GG 12.46 ± 1.31). All WT mice reached criterion by day 10 of training (14.94 ± 1.6 s).
BPN's effects in the NIH test are genotype dependent
Three doses of BPN were selected based on previous behavioral studies conducted in male C57BL/6 J mice (Falcon et al., 2015) , 0.25, 0.5 and 1 mg/kg, Mice were exposed to a novel environment and the latency to consume food was measured 24 h following a single injection of BPN (see Fig. 2) . A significant main effect of treatment on latency to eat was observed in WT mice (F 3, 27 ¼ 3.085, p ¼ 0.044, Fig. 2A ). Dunnett's multiple comparison tests revealed that BPN effectively reduced the latency to consume food at doses of 0.25 mg/kg (p < 0.05) and 0.5 mg/kg (p < 0.05). No effect was observed with the highest dose of 1 mg/kg. For subsequent experiments, 0.25 mg/kg of BPN was used. Next female mice derived from the Oprm1 A112G mouse model were studied in the NIH test 24 h post BPN administration (Fig. 2B) . A significant genotype Â treatment interaction was detected for the latency to consume food in the novel cage (F 2, 40 ¼ 3.394, p ¼ 0.0435). Tukey's multiple comparisons revealed that BPN (0.25 mg/kg) produced a robust reduction of latencies in AA mice (p < 0.05). BPN failed to reduce latencies in AG and GG mice. In a separate cohort of mice, the effects of the anxiolytic CDP were tested 30 min post injection (Fig. 2C ). CDP produced a significant reduction of approach latency across all three groups (F 1, 37 ¼ 74.92, p < 0.001) with no significant genotype Â treatment interaction, indicating that the effects of the genotype in this test are specific to MOR binding ligands.
The motoric effects of BPN are diminished in mice with the GG genotype
Mice were placed in the arena 30 min following BPN administration and locomotor activity was evaluated for 1 h. Significant genotype Â treatment interactions were detected for crosses (F 2, 72 ¼ 4.165, p ¼ 0.019, Fig. 3A ) and rearing (F 2, 72 ¼ 3.29, p ¼ 0.043, Fig. 3B ) during the testing period. BPN significantly increased the number of crosses in AA (p < 0.001) and AG (p < 0.001) mice compared to vehicle treated controls. This effect was significantly blunted in GG carriers compared to AA mice (p < 0.05). Interestingly, both AG and GG mice failed to exhibit a significant increase in rearing behavior post-BPN administration compared to their AA littermates (p < 0.01).
BPN's behavioral effects in the FST are unaffected by Oprm1 A112G polymorphism
The effects of BPN (0.25 mg/kg) in the FST were measured 24 h post injection, (see Fig. 4 ). There was a significant main effect of treatment on immobility scores in the FST (F 2, 56 ¼ 5.913, p ¼ 0.018), with no significant genotype Â treatment interaction. BPN decreased immobility scores in all three groups.
Discussion
Buprenorphine, the mixed partial agonist of opioid receptors, is most widely associated with the treatment of opioid addiction. However, at lower doses it is also used to control moderate acute and chronic pain. Despite the large body of work examining the OPRM1 A118G SNP in pain and analgesia, no clinical data is available describing the interaction between this SNP and BPN treatment. Therefore, the goal of these studies was to evaluate the impact of Three doses of BPN were tested in WT female C57BL/6 J mice (n ¼ 7e8 per group) to established the optimal dose of BPN for investigation in tests of depression and anxiety ( Fig. 2A) . 24 h following a single injection, the latency to approach and eat food in WT mice was reduced with 0.25 mg/kg and 0.5 mg/kg of BPN compared to vehicle treated mice, the symbol * indicates p < 0.05. Fig. 2B depicts the effects of the Oprm1 A112G polymorphism on the effects of BPN in the NIH task AA n ¼ 8e10, AG n ¼ 8, and GG n ¼ 6.24 h following a single injection, BPN (0.25 mg/kg) significantly reduced the latency to approach and consume food in AA but not AG/GG carriers (* represents p < 0.05). Conversely, in a separate cohort of mice, CDP (10 mg/kg) tested 30 min post injection readily reduced latency to consume food in all genotypes, AA n ¼ 6, AG n ¼ 8e9, and GG n ¼ 7, Fig. 2C . The symbol *** indicates a p < 0.001 compared to vehicle treated controls within each genotype. Fig. 3 . BPN-induced locomotor activity is significantly attenuated in GG mice. Mice were placed in the testing arena 30 min post BPN administration and observed for a period of 1 h, AA n ¼ 15e17, AG n ¼ 10, and GG n ¼ 13. Marked decreases in BPNinduced increases in the number of crosses (Fig. 3A) and rearing (Fig. 3B) the A112G SNP on the behavioral effects of BPN measured using murine models of pain sensitivity, locomotor hyperactivity, anxiety and antidepressant effects. The results demonstrate that MORdependent behavioral effects of BPN including pain sensitivity, locomotor hyperactivity and approach behavior in the NIH test, are modified by genetic variation in the A112G SNP with the A carrier being most responsive to drug effects. In contrast, the effects of BPN in the FST, mediated by the blockade of KORs, was not altered by genetic variation. These results suggest that the A118G SNP in humans is likely to contribute significant genetic variation in the pharmacological effects of BPN that can be attributed to MORs. Although the analgesic action of BPN is mediated via MOR agonism and modulated by KOR, delta opioid receptors and nociceptin/orphanin FQ (N/OFQ) receptors (Lutfy et al., 2003) , pharmacological and genetic blockade of opioid receptors confirmed that MORs alone are necessary for the analgesic properties of BPN (Grinnell et al., 2016; Ide et al., 2004) . In the present studies, we demonstrate that the antinociceptive effects of BPN are dependent on the Oprm1 A112G SNP. BPN-mediated antinociception was significantly reduced in AG mice and almost entirely absent in GG mice compared to their AA littermates. Although no genotype differences in baseline thermal sensitivity were observed in this study, it is possible that differences could be more apparent with prior exposure to pain or indeed in a different behavioral test of pain. The data presented here agrees with prior observations in male and female GG mice, which exhibited blunted morphine-mediated antinociception compared to controls (Mague et al., 2009) . Furthermore, studies conducted in humans report that G carriers consume greater quantities of morphine without comparable pain relief (Chou et al., 2006a (Chou et al., , 2006b ). This is of particular concern given the current opioid epidemic, with persistent use of higher doses of pain medications these patients are at increased risk to develop substance abuse disorders. Our data supports the hypothesis that the therapeutic benefits of BPN in the treatment of pain will be significantly limited in humans with the OPRM1 A118G SNP. Most pharmacogenetic studies to date have examined the effects of OPRM1 A118G in the context of post-operative pain relief; however, these data suggest that future studies should examine clinical outcomes of BPN in chronic pain treatment.
C57BL/6J mice typically display robust increases in locomotor activity following acute administration of morphine (Crawley et al., 1997) and BPN (Falcon et al., 2015) , that are known to be mediated by MORs (Hall et al., 2004) . In the present study, the magnitude of hyperactivity induced by BPN was significantly diminished in GG mice. GG mice exhibited significant attenuation of horizontal activity (the number of crosses) and no vertical activity (rearing behavior) following BPN administration compared to AA mice. AG mice showed an intermediate effect of BPN, exhibiting similar horizontal activity to those of their AA littermates but a marked reduction in vertical activity in response. These findings in Oprm1 A112G females are consistent with previous studies where both male and female GG mice failed to exhibit behavioral sensitization to repeated administration of morphine (Mague et al., 2009) . These data highlight the powerful impact of the genotype on BPN's behavioral effects.
As BPN is now being considered as a potential therapeutic for MDD, we evaluated the impact of the Oprm1 A112G SNP on two distinct rodent behavioral tests relevant to anxiety and depression, the NIH test and FST respectively. Hyponeophagia tasks are sensitive to the acute effects of anxiolytics and antidepressants only after chronic administration (Dulawa and Hen, 2005) . In agreement with previous findings in males treated with BPN or a combination of BPN/naltrexone (Almatroudi et al., 2015; Falcon et al., 2015) , we now confirm that BPN is also efficacious in females. BPN (0.25 and 0.5 mg/kg) reduced the latency to consume palatable food in the NIH test 24 h post treatment in WT female C57BL/6J mice. It is proposed that blockade of MOR mediates this anxiolytic action, as MOR agonism is prevented by this dose of BPN 24 h post treatment (Robinson et al., 2016) . In the Oprm1 A112G mouse model, BPN produced a robust effect in the AA mice but failed to diminish the anxiogenic effects of the novel environment in AG and GG mice, suggesting that altered genetic signaling at MORs mediated these behavioral differences. In agreement with this, we previoulsy demonstrated that approach behavior in the NIH test was blocked by the selective MOR antagonist cyprodime and in male Oprm1 À/À mice (Robinson et al., 2016) . Conversely, we showed that the prototypical benzodiazepine CDP was highly efficacious across all genotypes, demonstrating the specific ability of Oprm1 A112G SNP to attenuate the efficacy of MOR compounds. These data highlight the potential pharmacogenetic implications of the OPRM1 A118G SNP for the efficacy of BPN in the treatment of mood disorders, particularly in relation to anxiety.
Interestingly, a considerable genotype difference in the number of days to reach criterion was observed during the NIH training phase. GG mice exhibited higher latencies in the home cage compared to AA mice during the first seven days of training. This observation replicates the pronounced delay in reaching criterion observed in male Oprm1 -/-mice (Robinson et al., 2016) . The hedonic value of food is regulated at the level of the nucleus accumbens, by opioid regulated changes in dopamine (DA) and GABAergic neurotransmission and MOR antagonists are known to block feeding (Echo et al., 2001) . However, the G allele did not significantly alter food consumption in the experiments reported herein. Despite exhibiting higher levels of neophobia during training, AG and GG mice ate equivalent amounts of peanut butter chips compared with AA mice during the training phase. Moreover during the later training days AG mice consumed even greater levels of food compared to both AA and GG mice. These observations are in line with clinical studies that report associations of the OPRM1 A118G SNP with binge eating (Davis et al., 2009 ) and aberrant food reward in obese individuals (Carpenter et al., 2013) . Moreover, GG mice also exhibit increased social hedonic behavior compared to AA mice (Briand et al., 2015) suggesting that the overall valence of reward is considerable altered by the Oprm1 A112G SNP. Previously, we showed that BPN's antidepressant action in the FST is mediated via KORs (Falcon et al., 2016) . In accordance with these findings, BPN's activity in the FST was not altered by A112G genotype, as immobility scores in all three genotypes were significantly decreased compared to their respective controls. There is considerable evidence that KOR antagonists produce antidepressant-like behavioral effects in the FST Mague et al., 2003; McLaughlin et al., 2003) , but all of these studies involved male rodents. There has been limited information regarding the effects of KOR ligands in females in behavioral tests for antidepressant and anxiolytic drugs. Previously it was reported that the irreversible KOR binding ligand 2-(3,4-dichlorophenyl)eNmethyl-N-((1S)-1-(3-isothiocyanatophenyl)-2-(1-pyrrolidinyl) ethyl)acetamide hydrochloride (DIPPA, 1 mg/kg) failed to reduce immobility in female Swiss mice (Kaster et al., 2007) , but the dose used in this study was probably too low . Overall our data suggest that the Oprm1 A112G selectively diminished the efficacy of BPN in MOR but not KOR mediated behaviors.
The molecular basis of MOR activation and blockade is associated with specific signal transduction pathways which may interact with the OPRM1 A118G (Knapman and Connor, 2015) . In vitro assessment of BPN using CHO and AtT-20 cells expressing the OPRM1 A118G variant (N40D) illustrate the significant impact of the A118G SNP on BPN signaling (Knapman et al., 2014) . The N40D variant demonstrated a 50% reduction in BPN efficacy. Moreover, the ability of BPN to induced phosphorylation of ERK1/2 was reduced by 60%. In contrast activation of inwardly rectifying potassium channels (GIRKs) was unaltered by genotype. Conversely, in HEK239 cells, no effect of genotype was observed on suppression of Ca 2þ channel inhibition following BPN administration . These contradictory findings may be a result of cell specific differences in Ga and bg subunits, that mask genotype dependent changes in BPN mediated second messenger coupling. Furthermore, Melief and colleagues proposed that the analgesic tolerance to acute morphine and buprenorphine is JNK-mediated, and that this is associated with a significant lack of receptor internalization. In contrast, under the same conditions fentanyl, methadone and oxycodone induce robust GRK/b-arrestinedependent MOR internalization (Melief et al., 2010) . It is possible that differences such as those in b-arrestin-dependent internalization which is associated with rapid development of tolerance (Dang and Christie, 2012; Raehal and Bohn, 2011) , may alter the sensitivity of compounds to the effects of OPRM1 A118G polymorphism. These studies show that the Oprm1 A112G SNP altered the behavioral effects of BPN in tests relevant to pain sensitivity, locomotor activity and anxiety in female mice. Although male mice with the Oprm1 A112G SNP were not evaluated with BPN here, male Oprm1 A112G mice have demonstrated similar genotype differences to morphine-mediated antinociception and locomotor activity (Mague et al., 2009 ). Thus no sex-dependent baseline difference have been noted for the behavioral assays evaluated in these studies. However, consideration of sex-differences in other tasks is important because sex-specific associations of the G allele have been reported for conditioned place preference and morphine withdrawal, where females developed morphine preference and significant aversion following naloxone-precipitated withdrawal compared to males which were protected by the G allele (Mague et al., 2009) . Furthermore, females are at increased risk for the development of chronic pain than males (Greenspan et al., 2007) . In addition, clinical studies revealed that compared to their male contemporaries, female carriers of the G allele exhibited blunted stress reactivity (Lovallo et al., 2015) , elevated levels of persistent pain (Hasvik et al., 2014; Olsen et al., 2012; Sia et al., 2008) and reductions in the reinforcing value of nicotine (Ray et al., 2006) . As such, in other behavioral tests where sex differences are apparent, divergent effects of BPN may be observed in males and females. This should be considered in the future evaluation of BPN in preclinical and clinical studies. Overall the data presented here provide a compelling rationale to conduct clinical evaluation of the consequences of the OPRM1 A118G polymorphism in relation to the therapeutic effects of BPN.
